Bortezomib vs Carfilzomib
Research Verdict
Carfilzomib is the stronger research reference for the stated comparison criteria. Bortezomib: FDA approved 2003 (Velcade), VISTA trial and multiple Phase 3 RCTs establishing it as backbone of myeloma therapy.
Quick Answers
Which is better, Bortezomib or Carfilzomib?
Carfilzomib is the stronger research reference for the stated comparison criteria. Bortezomib: FDA approved 2003 (Velcade), VISTA trial and multiple Phase 3 RCTs establishing it as backbone of myeloma therapy.
What is the key difference between Bortezomib and Carfilzomib?
Bortezomib is a reversible proteasome inhibitor with significant peripheral neuropathy (up to 30%); carfilzomib is an irreversible proteasome inhibitor with less neuropathy but higher cardiovascular toxicity risk - different toxicity profiles that drive clinical selection.
Evidence Comparison
Bortezomib: FDA approved 2003 (Velcade), VISTA trial and multiple Phase 3 RCTs establishing it as backbone of myeloma therapy. Carfilzomib: FDA approved 2012 (Kyprolis), ENDEAVOR trial (Dimopoulos et al. Lancet Oncol 2016, n=929) showing superior PFS vs. bortezomib (18.7 vs. 9.4 months). Both have extensive Phase 3 data; carfilzomib demonstrated head-to-head superiority.
Evidence Context Favoring Bortezomib
First-line myeloma therapy backbone, lower cost, subcutaneous administration convenience, or when cardiovascular risk is a concern.
Evidence Context Favoring Carfilzomib
Relapsed/refractory myeloma, bortezomib-resistant disease, or when peripheral neuropathy is the limiting toxicity - carfilzomib showed superior PFS in ENDEAVOR.
Side-by-Side Snapshot
| Evidence grade | Bortezomib: Level A Carfilzomib: Level A |
|---|---|
| Research status | Bortezomib: FDA Approved Carfilzomib: FDA Approved |
| Primary category | Bortezomib: Immune Support Carfilzomib: Immune Support |
| Cited studies | Bortezomib: 3 Carfilzomib: 3 |